Abstract
The systematic evolution of ligands by exponential enrichment (SELEX) is a combinatorial oligonucleotide library- based in vitro selection approach in which DNA or RNA molecules are selected by their ability to bind their targets with high affinity and specificity, comparable to those of antibodies. Nucleic acids with high affinity for their targets have been selected against a wide variety of compounds, from small molecules, such as ATP, to membrane proteins and even whole organisms. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands, also known as aptamers, for a wide range of proteins of importance for therapy and diagnostics, such as growth factors and cell surface antigens. The number of aptamers generated as inhibitors of various target proteins has increased following automatization of the SELEX process. Their diagnostic and therapeutic efficacy can be enhanced by introducing chemical modifications into the oligonucleotides to provide resistance against enzymatic degradation in body fluids. Several aptamers are currently being tested in preclinical and clinical trials, and aptamers are in the process of becoming a new class of therapeutic agents. Recently, the anti-VEGF aptamer pegaptanib received FDA approval for treatment of human ocular vascular disease.
Keywords: SELEX, aptamer, therapeutic agent, high-throughput screening
Combinatorial Chemistry & High Throughput Screening
Title: DNA and RNA Aptamers: From Tools for Basic Research Towards Therapeutic Applications
Volume: 9 Issue: 8
Author(s): Henning Ulrich, Cleber A. Trujillo, Arthur A. Nery, Janaina M. Alves, Paromita Majumder, Rodrigo R. Resende and Antonio H. Martins
Affiliation:
Keywords: SELEX, aptamer, therapeutic agent, high-throughput screening
Abstract: The systematic evolution of ligands by exponential enrichment (SELEX) is a combinatorial oligonucleotide library- based in vitro selection approach in which DNA or RNA molecules are selected by their ability to bind their targets with high affinity and specificity, comparable to those of antibodies. Nucleic acids with high affinity for their targets have been selected against a wide variety of compounds, from small molecules, such as ATP, to membrane proteins and even whole organisms. Recently, the use of the SELEX technique was extended to isolate oligonucleotide ligands, also known as aptamers, for a wide range of proteins of importance for therapy and diagnostics, such as growth factors and cell surface antigens. The number of aptamers generated as inhibitors of various target proteins has increased following automatization of the SELEX process. Their diagnostic and therapeutic efficacy can be enhanced by introducing chemical modifications into the oligonucleotides to provide resistance against enzymatic degradation in body fluids. Several aptamers are currently being tested in preclinical and clinical trials, and aptamers are in the process of becoming a new class of therapeutic agents. Recently, the anti-VEGF aptamer pegaptanib received FDA approval for treatment of human ocular vascular disease.
Export Options
About this article
Cite this article as:
Ulrich Henning, Trujillo A. Cleber, Nery A. Arthur, Alves M. Janaina, Majumder Paromita, Resende R. Rodrigo and Martins H. Antonio, DNA and RNA Aptamers: From Tools for Basic Research Towards Therapeutic Applications, Combinatorial Chemistry & High Throughput Screening 2006; 9 (8) . https://dx.doi.org/10.2174/138620706778249695
DOI https://dx.doi.org/10.2174/138620706778249695 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Controversies in Anticoagulant Therapy in Vitreo-Retinal Surgery
Current Pharmaceutical Design Association and Causal Relationship of Midlife Obesity and Related Metabolic Disorders with Old Age Cognition
Current Alzheimer Research Bleeding and Acute Coronary Syndromes: Defining, Predicting, and Managing Risk and Outcomes
Current Drug Targets Oxidative Stress as a Regulator of Murine Atherosclerosis
Current Drug Targets Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Interleukins Involved in Inflammatory Bowel Disease as New Therapeutic Targets
Current Immunology Reviews (Discontinued) The Effect of Anti-B-cell Therapy on the Development of Atherosclerosis in Patients with Rheumatoid Arthritis
Current Pharmaceutical Design Update on the Molecular Genetic Studies of Behcets Disease
Current Rheumatology Reviews Physical Activity and Hypertension: Evidence of Cross-Sectional Studies,Cohort Studies and Meta-Analysis
Current Hypertension Reviews Macrovascular Protecting Effects of Berberine through Anti-inflammation and Intervention of BKCa in Type 2 Diabetes Mellitus Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology Virally Encoded G Protein-Coupled Receptors: Targets for Potentially Innovative Anti-Viral Drug Development
Current Drug Targets An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan Protects Against Neurological Deficits and Prolongs Survival in Spontaneously Hypertensive Rats Stroke-Prone (SHR-SP) Infused with Ang II
Vascular Disease Prevention (Discontinued) Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review of Recent Data
Current Psychopharmacology Predictive Factors of follow-up Non-attendance and Mortality Among Adults with Type 2 Diabetes Mellitus- an Analysis of the Malaysian Diabetes Registry 2009
Current Diabetes Reviews Soluble RAGE-Modulating Drugs: State-of-the-Art and Future Perspectives for Targeting Vascular Inflammation
Current Vascular Pharmacology Fibrinolytic Factors in Liver Fibrosis
Current Pharmaceutical Biotechnology COVID-19: Epidemiology, Pathology, Diagnosis, Treatment, and Impact
Current Pharmaceutical Design